NEW YORK (GenomeWeb News) – Vermillion today reported that it had first-quarter revenues of $53,000, compared to $21,000 in the first quarter of 2007, and that it cut its net loss 20 percent year over year.
 
The Fremont, Calif.-based firm is developing molecular diagnostic tests and expects to file its ovarian tumor triage test, called OVA1, with the US Food and Drug Administration within the next couple of months. It also is conducting clinical trials on a test for peripheral arterial disease.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.